Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea

Clalit Health Services

Status and phase: Withdrawn; Phase 4

Conditions: Rosacea

Treatments: Device: Intense Pulsed Light (M22); Drug: Bromonide 0.33% gel

Study type: Interventional

Funder types: Other

Identifiers

NCT03053700

0682-16RMC

Details and patient eligibility

About

This is an interventional and prospective study. The study is designed to evaluate the additional benefits of a combination of IPL treatment and local application of Bromonide 0.33% gel in the treatment of erythematotelangiectatic (ETR) and papulopustular (PPR).

Full description

Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. In addition half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient (male or female) must be over 18 yaers old of age and fulfil one of the following:

  1. Suffer from ETR
  2. Suffer from PPR
  3. Suffer from a combination of ETR and PPR.

Exclusion criteria

• 1.Under 18 years old of age. 2.Pregnant women. 3.Systemic treatment of rosacea at the previous six months before enrollment. 4.Topical treatment of rosacea at the previous one month before enrollment. 5.Phymatous or occular rosacae.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

0 participants in 2 patient groups

Treatment with bromonide 0.33% gel

Active Comparator group

Description:

Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.

Treatment:

Drug: Bromonide 0.33% gel

Treatment with bromonide 0.33% gel & IPL

Active Comparator group

Description:

Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.

Treatment:

Device: Intense Pulsed Light (M22)

Drug: Bromonide 0.33% gel